BRIEF published on 09/15/2026 at 15:40, 2 months 7 days ago Revive Therapeutics Aims to Expand Bucillamine Portfolio Intellectual Property Orphan Diseases Medical Countermeasures Government Partnerships Bucillamine
PRESS RELEASE published on 09/15/2026 at 15:35, 2 months 7 days ago Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases Revive Therapeutics Ltd. outlines strategy to build protected bucillamine franchise for medical countermeasures, rare diseases, and government preparedness programs Rare Diseases Medical Countermeasures Revive Therapeutics Ltd. Bucillamine Franchise Government Preparedness
BRIEF published on 08/19/2026 at 20:40, 3 months 2 days ago Revive Therapeutics Proposes Shares for Debt Settlement Debt Settlement Canadian Securities Exchange Shares Issuance Revive Therapeutics Biodefense Research
PRESS RELEASE published on 08/19/2026 at 20:35, 3 months 2 days ago Revive Therapeutics Announces Proposed Shares for Debt Settlement Revive Therapeutics Ltd. announces proposed debt settlement by issuing Settlement Shares to settle outstanding trade payables. Subject to CSE approval Debt Settlement Settlement Shares CSE Approval Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/19/2026 at 14:45, 3 months 3 days ago Revive Therapeutics Advances Biodefence Strategy with Bucillamine Medical Countermeasures Pandemic Preparedness Government Partnerships Bucillamine Biodefence
PRESS RELEASE published on 08/19/2026 at 14:40, 3 months 3 days ago Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio Revive plans to expand bucillamine use in biodefence with positive DRDC findings, government opportunities, and complementary therapies, focusing on medical countermeasures Bucillamine Biodefence Revive DRDC Government Opportunities
BRIEF published on 08/15/2026 at 00:55, 3 months 7 days ago Revive Therapeutics Grants 15.5 Million Stock Options Stock Options Life Sciences Biodefense Pandemic Preparedness Revive Therapeutics
PRESS RELEASE published on 08/15/2026 at 00:50, 3 months 7 days ago Revive Therapeutics Reports Grant of Options Revive Therapeutics Ltd. authorized the grant of 15,500,000 incentive stock options to key team members. The options aim to drive performance and incentivize excellence in advancing corporate objectives Stock Options Incentive Pandemic Preparedness Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/12/2026 at 14:00, 3 months 10 days ago Revive Therapeutics Announce Positive Study Results on Bucillamine for Nerve-Agent Exposure Bucillamine Revive Therapeutics Nerve-agent Research DRDC Study Biodefence
PRESS RELEASE published on 08/12/2026 at 13:55, 3 months 10 days ago Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study Revive Therapeutics announces positive results from DRDC research study on bucillamine in nerve-agent exposure model, showing preservation of GABA receptors. Further studies planned Bucillamine Revive Therapeutics DRDC Research Study Nerve-agent Exposure GABA Receptors
Published on 11/20/2026 at 15:00, 2 days 1 hour ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 2 days 1 hour ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 2 days 2 hours ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 2 days 2 hours ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 2 days 2 hours ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 1 day 16 hours ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 21:36, 1 day 18 hours ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 19:26, 1 day 20 hours ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 1 day 21 hours ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:34, 1 day 21 hours ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 1 day 22 hours ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 2 days 21 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 08:30, 3 days 7 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing